【摘要】 目的 评价西格列汀治疗T2DM的疗效和安全性。 方法 通过检索数据库最终纳入12项随机对照试验并进行Meta分析。 结果 与安慰剂相比，西格列汀可降低HbA1c(WMD=﹣0.77，95%CI：﹣0.80~﹣0.66，P<0.01)、FPG(WMD=﹣1.25，95%CI：﹣1.50~﹣1.01，P<0.01)、2 hPG(WMD=﹣2.61，95%CI：﹣3.04~﹣2.17，P<0.01)。西格列汀降低HbA1c效果较GLP-1类似物差(WMD=0.47，95%CI：0.32~0.63，P<0.01)，降低FPG效果较GLP-1类似物、二甲双胍差(WMD=1.25，95%CI：0.99~1.52，P<0.01;WMD=0.88，95%CI：0.56~1.20，P<0.01)。西格列汀降低低血糖发生率与安慰剂比较差异无统计学意义(RR=1.44，95%CI：0.79~2.62，P=0.23)。 结论 西格列汀可使T2DM患者有效控制血糖，且低血糖发生率低，为T2DM患者提供一种安全有效的选择，但降糖效果较GLP-1类似物、二甲双胍差。

　　【关键词】西格列汀;糖尿病，2型;Meta分析

　　【Abstract】 Objective To assess the efficacy and safety of sitagliptin in the treatment of T2DM. Methods Retrieval with computer from the medicine databases, a total of 12 studies were selected, and meta-analysis was performed. Results Compared with placebo, HbA1c, FPG, 2 hPG were decreased with sitagliptin(WMD=﹣0.77，95%CI：﹣0.80~﹣0.66，P<0.01;WMD=﹣1.25，95%CI：﹣1.50~﹣1.01，P<0.01;WMD=﹣2.61，95%CI：﹣3.04~﹣2.17，P<0.01). Sitagliptin was shown to be less effective in reducing HbA1c when compared with GLP-1 nanlogue(WMD=0.47，95%CI：0.32~0.63，P<0.01). Sitagliptin was also shown to be less effective in reducing FPG when compared with GLP-1 nanlogue and metformin(WMD=1.25，95%CI：0.99~1.52，P<0.01;WMD=0.88，95%CI：0.56~1.20，P<0.01). There was no statistically significant difference in the risk of hypoglycemia with sitagliptin,compared to placebo(RR=1.44，95%CI：0.79~2.62，P=0.23). Conclusion Sitagliptin is effective in glycemic control with a low risk of hypoglycemia for T2DM patients, so it can provide an effective safe choice for them, but sitagliptin is less effective in reducing blood glucose when compared with GLP-1 nanlogue and metformin.

　　【Key words】Sitagliptin;Diabetes mellitus，type 2;Meta-analysis